Organogenesis Holdings Inc - Class A risk profile
42 Elevated one input has moved against it
Measured 21 October 2026 from ORGO's filed statements. Recomputed nightly.
42 (Elevated), driven by Cash conversion at 93, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 82 | Acute | Volatile | One-year price volatility — 77.9% |
| Operating pressure | 26 | Normal | Easing | Operating-margin drift — +3.0 percentage points |
| Cash conversion | 93 | Acute | Worsening | Capital spending against operating cash — -1.37x |
| Leverage and coverage | 3 | Contained | Easing | Current ratio — 3.62x |
| Competitive position | 41 | Elevated | Stable | R&D-intensity gap against peers — -21.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Organogenesis Holdings Inc - Class A